Ofranergene obadenovec is under clinical development by Vascular Biogenics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ofranergene obadenovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ofranergene obadenovec overview
Ofranergene obadenovec (VB-111) is under development for the treatment of advanced metastatic cancer, recurrent glioblastoma multiforme (rGBM), melanoma, metastatic lung cancer, thyroid cancer, metastatic gastrointestinal cancer, colon cancer, peritoneal cancer, fallopian tube cancer, uterine papillary serous carcinomas, metastatic colorectal cancer, glioblastoma, gliosarcoma and gynecologic malignant mixed Mullerian tumors. It is administered as an intravenous infusion. The drug candidate is a next generation anti-angiogenesis therapy based on vascular targeting system (VTS) technology. The drug candidate was also under development for the treatment of renal cell carcinoma, neuroendocrine tumors, epithelial ovarian cancer and metastatic lung cancer.
Vascular Biogenics overview
Vascular Biogenics, dba VBL Therapeutics, is a biopharmaceutical company. It discovers, develops and commercializes gene-therapy medicines for the treatment of cancer and inflammatory diseases. The company’s lead product candidate VB-111, a gene-based biologic agent is developed to treat recurrent glioblastoma, colon, ovarian, thyroid cancer and solid tumors. Its pipeline products include VB 201 and VB 703, oral small molecules being developed through lecinoxoids platform for treating cardiovascular diseases, liver and renal fibrosis. Vascular Biogenics uses its proprietary vascular targeting system technology to enable systemic administration of gene therapy and improve angiogenic blood vessels. The company is investigating its VB-600 platform targeting MOSPD2 for treating cancers and inflammatory diseases. Vascular Biogenics is headquartered in Modiin, Tel Aviv, Israel.
For a complete picture of Ofranergene obadenovec’s drug-specific PTSR and LoA scores, buy the report here.